Literature DB >> 20202806

Point-of-care Arkansas method for measuring adherence to treatment with isoniazid.

Renata L Guerra1, Marcus B Conde, Anne Efron, Carla Loredo, Gisele Bastos, Richard E Chaisson, Jonathan E Golub.   

Abstract

We evaluated the accuracy of a point-of-care test designed to measure adherence to isoniazid (INH) preventive therapy in a hospital setting in Rio de Janeiro, Brazil. Patients on treatment with daily INH and patients not receiving INH were included. Sensitivity and specificity of the test were 84%/98% at the first minute, and 95%/98% at the fifth minute, respectively. Among smokers, sensitivity and specificity was reduced (80%/89% at the fifth minute, respectively), but only 17% smoked. This test accurately detected INH metabolites 24h following directly observed INH intake, though sensitivity and specificity may be compromised by tobacco smoke exposure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202806      PMCID: PMC2862798          DOI: 10.1016/j.rmed.2010.02.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  11 in total

1.  Urine testing to monitor adherence to TB preventive therapy.

Authors:  Sharon Perry; Melbourne F Hovell; Elaine Blumberg; Jill Berg; Alicia Vera; Carol Sipan; Norma Kelley; Kathleen Moser; Antonino Catanzaro; Larry Friedman
Journal:  J Clin Epidemiol       Date:  2002-03       Impact factor: 6.437

2.  Evaluation of the Arkansas method of urine testing for isoniazid in South Africa.

Authors:  Y Hanifa; K Mngadi; J Lewis; K Fielding; G Churchyard; A D Grant
Journal:  Int J Tuberc Lung Dis       Date:  2007-11       Impact factor: 2.373

3.  A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail.

Authors:  M C White; J P Tulsky; P Reilly; H W McIntosh; T M Hoynes; J Goldenson
Journal:  Int J Tuberc Lung Dis       Date:  1998-06       Impact factor: 2.373

4.  Monitoring compliance with antituberculous treatment by detection of isoniazid in urine.

Authors:  J Elizaga; J S Friedland
Journal:  Lancet       Date:  1997-10-25       Impact factor: 79.321

5.  Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection.

Authors:  Tal Eidlitz-Markus; Avraham Zeharia; Gerald Baum; Marc Mimouni; Jacob Amir
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

6.  Point-of-care test to monitor adherence to anti-tuberculous treatment.

Authors:  Ruth Whitfield; Graham F Cope
Journal:  Ann Clin Biochem       Date:  2004-09       Impact factor: 2.057

7.  An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs.

Authors:  G A Ellard; P J Jenner; P A Downs
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

8.  Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention.

Authors:  Lawrence H Moulton; Jonathan E Golub; Betina Durovni; Solange C Cavalcante; Antonio G Pacheco; Valeria Saraceni; Bonnie King; Richard E Chaisson
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

9.  Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?

Authors:  Gavin J Churchyard; Katherine Fielding; Salome Charalambous; John H Day; Elizabeth L Corbett; Richard J Hayes; Richard E Chaisson; Kevin M De Cock; Badara Samb; Alison D Grant
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

10.  Testing for isoniazid. An evaluation of the Arkansas method.

Authors:  D E Schraufnagel; R Stoner; E Whiting; G Snukst-Torbeck; M J Werhane
Journal:  Chest       Date:  1990-08       Impact factor: 9.410

View more
  13 in total

1.  Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.

Authors:  V Amlabu; C Mulligan; N Jele; A Evans; D Gray; H J Zar; H McIlleron; P Smith
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

2.  Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia.

Authors:  U Egere; A Sillah; T Togun; S Kandeh; F Cole; A Jallow; A Able-Thomas; M Hoelscher; N Heinrich; P C Hill; B Kampmann
Journal:  Public Health Action       Date:  2016-12-21

3.  The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial.

Authors:  Sara Lodi; Nneka I Emenyonu; Kara Marson; Dalsone Kwarisiima; Robin Fatch; Michael G McDonell; Debbie M Cheng; Harsha Thirumurthy; Monica Gandhi; Carol S Camlin; Winnie R Muyindike; Judith A Hahn; Gabriel Chamie
Journal:  Trials       Date:  2021-05-20       Impact factor: 2.279

4.  Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients.

Authors:  Ioana Nicolau; Lulu Tian; Dick Menzies; Gaston Ostiguy; Madhukar Pai
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

5.  Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV.

Authors:  Emily A Kendall; Betina Durovni; Neil A Martinson; Solange Cavalacante; Katlego Masonoke; Valeria Saraceni; Limakatso Lebina; Anne Efron; Silvia Cohn; Sandy Chon; Richard E Chaisson; David W Dowdy; Jonathan E Golub
Journal:  AIDS       Date:  2020-01-01       Impact factor: 4.632

6.  Urine Biomarker Assessment of Infant Adherence to Isoniazid Prophylaxis.

Authors:  Sylvia M LaCourse; Daniel Leon; Nuttada Panpradist; Barbra A Richardson; Elizabeth Maleche-Obimbo; Jerphason Mecha; Daniel Matemo; Jaclyn N Escudero; John Kinuthia; Barry Lutz; Grace John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2021-01       Impact factor: 2.129

7.  Mobile Tuberculosis Treatment Support Tools to Increase Treatment Success in Patients with Tuberculosis in Argentina: Protocol for a Randomized Controlled Trial.

Authors:  Sarah Iribarren; Hannah Milligan; Kyle Goodwin; Omar Alfonso Aguilar Vidrio; Cristina Chirico; Hugo Telles; Daniela Morelli; Barry Lutz; Jennifer Sprecher; Fernando Rubinstein
Journal:  JMIR Res Protoc       Date:  2021-06-21

8.  Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic.

Authors:  Claudia C Dobler; Guy B Marks
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

9.  Adherence to tuberculosis therapy among patients receiving home-based directly observed treatment: evidence from the United Republic of Tanzania.

Authors:  Abdallah Mkopi; Nyagosya Range; Fred Lwilla; Saidi Egwaga; Alexander Schulze; Eveline Geubbels; Frank van Leth
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

10.  Protocol for a cluster randomised control trial evaluating the efficacy and safety of treatment for latent tuberculosis infection in recent migrants within primary care: the CATAPuLT trial.

Authors:  M Burman; A Copas; D Zenner; V Hickson; L Gosce; D Trathen; R Ashcroft; A R Martineau; I Abubakar; C Griffiths; H Kunst
Journal:  BMC Public Health       Date:  2019-11-29       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.